| Literature DB >> 24005052 |
Vladimir Bezrookove1, David De Semir1, Mehdi Nosrati1, Schuyler Tong1, Clayton Wu1, Suresh Thummala1, Altaf A Dar1, Stanley P L Leong1, James E Cleaver2, Richard W Sagebiel1, James R Miller1, Mohammed Kashani-Sabet1.
Abstract
Ulceration is an important prognostic factor in melanoma whose biologic basis is poorly understood. Here we assessed the prognostic impact of pleckstrin homology domain-interacting protein (PHIP) copy number and its relationship to ulceration. PHIP copy number was determined using fluorescence in situ hybridization (FISH) in a tissue microarray cohort of 238 melanomas. Elevated PHIP copy number was associated with significantly reduced distant metastasis-free survival (DMFS; P=0.01) and disease-specific survival (DSS; P=0.009) by Kaplan-Meier analyses. PHIP FISH scores were independently predictive of DMFS (P=0.03) and DSS (P=0.03). Increased PHIP copy number was an independent predictor of ulceration status (P=0.04). The combined impact of increased PHIP copy number and tumor vascularity on ulceration status was highly significant (P<0.0001). Stable suppression of PHIP in human melanoma cells resulted in significantly reduced glycolytic activity in vitro, with lower expression of lactate dehydrogenase 5, hypoxia-inducible factor 1 alpha subunit, and vascular endothelial growth factor, and was accompanied by reduced microvessel density in vivo. These results provide further support for PHIP as a molecular prognostic marker of melanoma, and reveal a significant linkage between PHIP levels and ulceration. Moreover, they suggest that ulceration may be driven by increased glycolysis and angiogenesis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24005052 PMCID: PMC3945648 DOI: 10.1038/jid.2013.369
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551
Figure 1PHIP copy number and its correlation with DMFS and DSS in melanoma patients. (a) Dual color FISH for PHIP locus, red, and centromere of chromosome 6, green, representative of low PHIP copy number, left panel, and high copy number, right panel. Scale bar = 20 Rm. (b) Kaplan-Meier analysis of DMFS in patients with low PHIP copy number (curve 1) versus patients with high PHIP copy number (curve 2). (c) Kaplan-Meier analysis of DSS in patients with low PHIP copy number (curve 1) versus patients with high PHIP copy number (curve 2).
Cox regression analysis of impact of various prognostic factors on DMFS of melanoma cohort (N = 231).
|
|
|
|
|
|---|---|---|---|
| Tumor thickness | 6.96 | 1.38 | .008 |
| High | 4.73 | 1.99 | .03 |
| Ulceration | 3.31 | 1.51 | .07 |
| Sex | 1.41 | 1.34 | .24 |
| Site | 0.92 | 1.24 | .34 |
| Age | 0.61 | 0.95 | .44 |
Cox regression analysis of impact of various prognostic factors on DSS of melanoma cohort (N = 231).
|
|
|
|
|
|---|---|---|---|
| Tumor thickness | 6.13 | 1.38 | .013 |
| High | 4.87 | 2.21 | .027 |
| Ulceration | 3.63 | 1.58 | .057 |
| Sex | 1.00 | 1.30 | .32 |
| Site | 0.81 | 1.24 | .37 |
| Age | 0.01 | 0.99 | .91 |
Logistic regression analysis of impact of various prognostic factors on incidence of ulceration in melanoma cohort (N = 228).
|
|
|
|
|
|---|---|---|---|
| Mitotic rate | 15.24 | 1.23 | .0001 |
| Tumor vascularity | 10.26 | 3.05 | .001 |
| Tumor thickness | 5.99 | 1.63 | .01 |
| High | 4.10 | 1.96 | .04 |
Figure 2Effects of shRNA-mediated suppression of PHIP in human melanoma cells. (a) Lactate production in C8161.9 cells expressing anti-PHIP shRNA versus control cells expressing anti-luc shRNA. Mean ± SE; N = 3. * denotes P < 0.003. (b) Western analysis of LDH5 and HIF1A in C8161.9 cells expressing anti-luc shRNA (control cells, lane 1) or anti-PHIP shRNA (lane 2). (c) Invasive capacity of C8161.9 stable transformants expressing anti-PHIP shRNA with or without the addition of methylpyruvate (MP). Mean ± SE; N = 3. * denotes P < 0.05. (d) ELISA assay of human VEGF levels produced by C8161.9 cells expressing anti-PHIP shRNA versus control cells expressing anti-luc shRNA. Mean ± SE; N = 3. * denotes P < 0.0001.
Figure 3Effects of PHIP expression on the angiogenic potential of C8161.9 human melanoma cells in vivo. (a) Representative images of H&E staining of subcutaneous tumors in nude mice. The left panel shows the growth pattern of C8161.9 cells expressing anti-luc shRNA, compared with C8161.9 cells expressing anti-PHIP shRNA (right panel). (b) Composite images of immunofluorescence detection of CD31, red, and DAPI, blue as counterstain. The left panel shows the staining pattern of CD31 in subcutaneous tumor with C8161.9 cells expressing anti-luc shRNA compared with C8161.9 cells expressing anti-PHIP shRNA (right panel). Scale bar = 100 Rm. (c) Composite images of CD31 staining pattern with higher magnification for tumors with C8161.9 cells expressing anti-luc shRNA (left panel), or anti-PHIP shRNA (right panel). Scale bar = 20 Rm. (d) Quantification of microvessel density (MVD) based on CD31 immunofluorescence positivity in tumors (six per group) with C8161.9 cells expressing either anti-luc shRNA or anti-PHIP shRNA. Mean ± SD. * denotes P < 0.02.